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Introduction
According to the Journal of
Anesthesia and Intensive Care,
Malignant Hyperthermia (MH) is an
uncommon disorder of skeletal
muscle, with autosomal dominant
inheritance triggered almost
exclusively by potent inhalational
agents and suxamethonium (Chan,
Bulger, Stowell, Gillies, Langton,
Street, and Pollock, 2017). Although
it is rare, it is a true medical
emergency which can lead to death
if left untreated. Mostly anesthesia
medications trigger the response so
it is imperative the anesthesia
providers along with the
postoperative nurses know the signs
and symptoms that trigger
malignant hyperthermia. It is a
hypermetabolic state triggered by
an abnormality of calcium release or
reuptake by the sarcoplasmic
reticulum with muscle contraction.
The incidence of MH in adults is one
in every 50,000 to 100,000 and
children is one in every 300,000 to
500,000 cases (Chan et al., 2017).
Since MH occurs in genetically
predisposed individuals, one must
go through an invasive muscle
biopsy procedure to get diagnosed.
The test is very expensive and has a
high false positive result. This topic
was chosen due to my future
interest as a practicing nurse
anesthetist. Researching MH will
prepare me and make me more
aware as an anesthesia provider.

Pathophysiological Process
Sign & Symptoms
Medical personnel should be
aware and recognize the signs and
symptoms of MH. The cardinal
sign of MH is hyperthermia, which
is relatively a late sign. MH can
occur very suddenly with muscle
rigidity or gradually and not show
the signs till in the post-operative
unit.
Signs and Symptoms include:
-Tachyarrhythmia’s in 96% of
cases
-Tachypnea in 85% due to rapidly
rising carbon dioxide level
-Acidosis in 80% due to lactic acid
and heat
-Oxygen saturation levels drop
during normal ventilation
-Generalized muscle rigidity in
80% is one of the earliest signs
(Hommertzheim & Steinke, 2006)
Therefore many complications
can occur due to the profound
impact on the body. Severe
complications such as metabolic
acidosis, bowel ischemia,
compartment syndrome of the
limbs, vital organ dysfunction,
acute renal failure, and
disseminated intravascular
coagulation. Other less severe
symptoms include muscle
weakness, lightheadedness, and
difficulty swallowing
(Hommertzheim & Steinke, 2006).
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Underlying
Pathophysiology
MH is a hypermetabolic state
triggered by an abnormality of calcium
release or reuptake by the
sarcoplasmic reticulum with severe
muscle contraction. In genetically
predisposed individuals the triggering
event resides in the skeletal muscle at
the level of calcium when it transfers
into the muscle cell. Therefore the
influx of calcium into the cell leads to
hypermetabolism which increases
carbon dioxide production, increases
oxygen consumption, and increases
sympathetic activity (Hommertzheim
& Steinke, 2006).
-The most common mutation is found
in the RYR1 gene on chromosome 19
that regulates the calcium pathway
for the sarcoplasmic reticulum. The
distribution of the mutation is varied
among ethnic groups (McGoldrick,
2017).
-The increase or surge of intracellular
hypercalcemia activates a cascade of
metabolic pathways that deplete ATP,
cause acidosis, membrane
destruction, and cell death
(McGoldrick, 2017).
-Testing can be performed to
determine susceptibility of MH with a
caffeine halothane contracture test
(CHCT). The CHCT test requires
invasive muscle biopsy from the thigh.
Only six centers in the United States
are approved for testing. A patient
must travel to a center in order to get
tested which is generally not covered
by insurance at $6,000
(Hommertzheim & Steinke, 2006).

Significance of Pathophysiology
-Knowing the pathophysiology of MH allows individuals to recognize the
signs and symptoms of MH faster. Also knowing the mechanism of action
allows for treatment. Two known triggering agents are succinylcholine and
halogenated volatile anesthetics (Hommertzheim & Steinke, 2006).
- Other triggers include butyrophenones, phenothiazines, various atypical
anti-psychotics, anti-dopaminergic drugs, and abrupt withdrawal of antiParkinson’s drugs (McGoldrick, 2017).
-Stop the trigger agent immediately and active the MH team to get help to
quickly stop the crisis to prevent it from progressing to life-threatening
conditions.

Implications for Nursing Care

Conclusion

The anesthesia staff along with the
registered nurses working in the
postoperative unit must know the
response plan for an MH event.
Chances for a successful outcome
will increase with a rapid, accurate
diagnosis and a coordinated, swift,
multidisciplinary team to deliver
the appropriate treatment (Dirksen,
Van Wicklin, Mashman, Neiderer,
Merritt, 2013). Therefore, proper
education and training is imperative
to all the necessary team members
based on the organizations
environment. Practice through
simulation and mock drills are
essential to ensure the staffs roles
are defined during a MH crisis.
Many facilities have a designated
emergency cart solely responsible
for a MH crisis. Staff must know
where the carts are located and
know how to use the equipment
within the carts. Perioperative
nurses also screen patients prior to
anesthesia and maybe able to
uncover red flags such as a prior
occurrence or known family
member who has experienced MH.

-MH is rare genetic ailment that is a
life-threating condition when
provoked by the administration of
anesthetic agents.

-If and MH event occurs the
procedure should be stopped
immediately unless emergent. If
the procedure must continue the
anesthesia team is responsible for
discontinuing all triggering
anesthetics and begin the
treatment for MH. Treatment
begins by hyperventilating the
patient with 100% oxygen and
administering a dose of dantrolene
sodium. Dantrolene is a skeletal
muscle relaxant that depresses
muscle contraction by decreasing
intracellular calcium concentration
(National Institute s of Health,
2018). Electrolyte replacement and
monitoring will have to be
corrected. The patient would most
likely be transferred to the
intensive care unit for monitoring
for the next day or two for
observation.

-The earliest signs of MH are
generally non-specific, which can
make MH very difficult to diagnose
by even experienced medical
professionals (Issak & Stiegler,
2016).
-Simulation and mock drills are
necessary to all anesthesia providers
and nurses know how to monitor
and treat a patient if MH develops.
-Testing is expensive and not
convenient for a majority of the
population.
-Before the introduction of
dantrolene, the mortality of MH was
84%. Now with proper monitoring
and education the mortality has
been reduced to 9% (Chan et. al,
2017).

References
Chan, T.Y., Bulger, T.F., Stowell,
K.M., Gillies R.L., Langton, E.E.,
Street, N.E., & Pollock, N.A.
(2017). Evidence of malignant
hyperthermia in patients
administered triggering agents
before malignant hyperthermia
susceptibility identified: missing
opportunities prior to diagnosis.
Anesthesia and Intensive Care
Journal, 45(6), 707-713.
Dirksen, S. H., Van Wicklin, S. A.,
Mashman, D. L., Neiderer, P., &
Merritt, D. R. (2013). Developing
Effective Drills in Preparation for
a Malignant Hyperthermia Crisis.
AORN Journal, 97(3), 330-352.
doi:10.1016/j.aorn.2012.12.009
Hommertzheim, R., & Steinke, E.
(2006). Home study program.
Malignant hyperthermia -- the
perioperative nurse's role.
AORN Journal, 83(1), 149-160.
Isaak, R. S., & Stiegler, M. P. (2016).
Review of crisis resource
management (CRM) principles in
the setting of intraoperative
malignant hyperthermia. Journal
Of Anesthesia, 30(2), 298-306.
doi:10.1007/s00540-015-2115-8
McGoldrick, Kathyrn E., (2017).
Malignant Hyperthermia: An
Update. Current Review for
Nurse Anesthetisits, 39(23), 297308
National Institutes of Health.
PubChem. (2017). Dantrolene
Sodium. Retrieved July 11, 2018
from:https://pubchem.ncbi.nlm.nih
.gov/compound/dantrolene_sodiu
m

